REVIEW article
Front. Med.
Sec. Gastroenterology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1630788
This article is part of the Research TopicResearch on Biomarkers for Immunotherapy in Gastrointestinal Tumors: Basic Exploration and Clinical ApplicationView all 4 articles
Applications and Advances of Multi-Omics Technologies in Gastrointestinal Tumors
Provisionally accepted
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, Jinan，Shandong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Gastrointestinal tumors pose a significant clinical challenge due to their high heterogeneity and the difficulties in early diagnosis. The article systematically reviews the latest advances in multi-omics technologies in gastrointestinal tumor research, focusing on their contributions to early screening, biomarker discovery, and treatment optimization. Genomics reveals genetic characteristics and heterogeneity of tumors; transcriptomics helps identify molecular subtypes and potential therapeutic targets; proteomics provides important information on core proteins and the immune microenvironment; and metabolomics offers promising biomarkers for early diagnosis. Furthermore, emerging fields such as epigenomics, metagenomics, and lipidomics, through the construction of multiscale frameworks, have opened new paths for molecular subtyping and targeted therapy. By integrating these multi-dimensional data, Multi-omics integration enables a panoramic dissection of driver mutations, dynamic signaling pathways, and metabolic-immune interactions. However, challenges such as data heterogeneity, insufficient algorithm generalization, and high costs limit clinical translation. In the future, the integration of single-cell multi-omics, artificial intelligence, and deep learning technologies with multi-omics may offer more efficient strategies for the precise diagnosis and personalized treatment of gastrointestinal tumors. This essay attempts to methodically review the development of multi-omics technologies in gastrointestinal tumor research, with a focus on their functions in early screening, biomarker discovery, and treatment optimization, as well as the use of methodological references for the clinical translation of multi-omics-based precision diagnostic and therapeutic strategies.Multi-omics technologies refer to the integrated analysis of data from multiple omics levels, encompassing genomics, transcriptomics, proteomics, metabolomics, epigenomics, and metagenomics.Each omics technology has distinct characteristics and applications, as shown in Table 1. This article primarily explores the applications of multi-omics technologies in gastrointestinal tumors.
Keywords: Gastrointestinal tumors, multi-omics technologies, single-cell genomics, Early Screening, biomarkers, treatment optimization
Received: 18 May 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Liu, Gao, Cheng, Qi and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Haining Yu, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, Jinan，Shandong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.